What are you looking for?
Search
Slu-PP-332: A Multifaceted Exploration of Enhancing Physical Functionality
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE SOLELY FOR INFORMATION DISSEMINATION AND EDUCATIONAL PURPOSES.
The products provided on this website are intended exclusively for in vitro research. In vitro research (Latin: *in glass*, meaning in glassware) is conducted outside the human body. These products are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and must not be used to prevent, treat, or cure any medical condition, disease, or ailment. It is strictly prohibited by law to introduce these products into the human or animal body in any form.
1. Overview
Slu-PP-332, a synthetic estrogen receptor-related orphan receptor (ERR) agonist, can have positive effects on human health in multiple ways. From a chemical structural perspective, it belongs to a specific class of small-molecule compounds that can precisely bind to ERR receptors, thereby activating a series of physiological responses. Unlike traditional drugs or methods for regulating bodily functions, Slu-PP-332 exerts physiological regulation by targeting the relatively novel ERR receptor.
Figure 1 The chemical structure of Slu-PP-332.
2. Mechanism of Action
Energy Metabolism Regulation: Slu-PP-332 exhibits significant regulatory effects on energy metabolism. It activates the ERR receptor, enhancing energy expenditure. At the cellular level, it increases mitochondrial function and improves cellular respiratory efficiency, enabling cells to convert nutrients into energy more efficiently. In skeletal muscle cells, Slu-PP-332 induces the expression of related genes, promoting fatty acid oxidation, allowing fat to be utilized more fully as an energy source and reducing fat accumulation. These effects mimic the body's energy metabolism during exercise, enabling the body to maintain a high level of energy expenditure even at rest, which helps maintain a healthy weight and improve overall metabolic status.
Improved skeletal muscle function: In terms of skeletal muscle, Slu-PP-332 demonstrates positive effects. It can activate the acute aerobic exercise genetic program, which depends on the ERRα receptor. Studies have shown that after administering Slu-PP-332 to mice, there was an increase in type IIa oxidative skeletal muscle fibers, which enhances muscle endurance. Type IIa fibers have higher oxidative capacity, enabling more efficient use of oxygen to produce energy, thereby prolonging muscle activity duration. For humans, this suggests that Slu-PP-332 may help improve exercise endurance, potentially benefiting both athletes seeking to enhance performance and individuals aiming to enhance daily physical capabilities. Its enhancement of skeletal muscle mitochondrial function may also help reduce muscle fatigue and accelerate post-exercise recovery.
Cardiac function maintenance: Estrogen receptor-related orphan receptors ERRα and ERRγ are key regulators of cardiac metabolism. Mice lacking ERRα and ERRγ develop fatal cardiomyopathy and heart failure. As an effective ERR agonist, Slu-PP-332 plays a crucial role in maintaining cardiac function. Researchers induced heart failure in adult male mice via aortic coarctation (TAC) and then administered Slu-PP-332 for treatment. Slu-PP-332 treatment significantly improved the ejection fraction of the mice, an important indicator of cardiac pumping function, indicating enhanced cardiac contractility. It also improved mitochondrial ultrastructure, reduced cardiac fibrosis, and normalized the abnormal expression of related genes. These changes collectively contribute to maintaining the heart's normal structure and function. Slu-PP-332's improvement in cardiac function is attributed to its enhancement of mitochondrial function and regulation of fatty acid metabolism pathways, offering a new therapeutic approach for heart failure.
3. Applications
Sports Medicine Field: In sports medicine, Slu-PP-332 holds great potential for application. For athletes, it can serve as a novel performance-enhancing agent. By improving exercise endurance and reducing muscle fatigue, athletes can perform more effectively during training and competitions. Long-distance runners may experience extended exercise endurance limits and improved competition performance after use. For general fitness enthusiasts, Slu-PP-332 can help them achieve a more efficient state of energy metabolism during exercise, improve exercise effectiveness, reduce post-exercise muscle soreness and other discomfort, and promote physical recovery, enabling them to participate more actively in exercise and training. For those unable to engage in high-intensity exercise due to declining physical function, such as the elderly or patients with certain chronic diseases, Slu-PP-332 improves muscle function and energy metabolism, enabling them to engage in moderate exercise and thereby enhance their quality of life.
Metabolic disease treatment: In the treatment of metabolic diseases, Slu-PP-332 also demonstrates significant potential. Taking obesity as an example, it enhances energy expenditure and reduces fat accumulation, offering new treatment options for obese patients. Preclinical studies indicate that in diet-induced obese mice or ob/ob mouse models, administration of Slu-PP-332 effectively reduces body weight and improves insulin sensitivity. This is also significant for patients with type 2 diabetes, as insulin resistance is one of the key pathophysiological mechanisms of type 2 diabetes. Slu-PP-332 improves insulin sensitivity, thereby aiding in better control of blood glucose levels. For individuals with metabolic syndrome, Slu-PP-332 can comprehensively improve multiple metabolic disorders, such as dyslipidemia and hypertension, thereby reducing the risk of complications such as cardiovascular disease.
4. Conclusion
Heart disease prevention and treatment: Given Slu-PP-332's positive effects on cardiac function, it holds significant application value in the field of heart disease prevention and treatment. For heart failure patients, current treatment options are limited, but Slu-PP-332 improves cardiac function by enhancing mitochondrial function and regulating fatty acid metabolism, providing a new drug target for heart failure treatment. For populations at risk of heart disease, such as those with hypertension or coronary heart disease, Slu-PP-332 may play a preventive role by maintaining normal cardiac metabolism and function, thereby reducing the risk of heart disease. In summary, Slu-PP-332, as a compound with a unique mechanism of action, can improve bodily functions.
Sources
[1] Nasri H. New hopes on "SLU-PP-332" as an effective agent for weight loss with indirect kidney protection efficacy; a nephrology point of view[J]. Journal of Renal Endocrinology, 2024. https://api.semanticscholar.org/CorpusID:267189187.
[2] Billon C, Sitaula S, Banerjee S, et al. A Synthetic ERR$\alpha$ Agonist Induces an Acute Aerobic Exercise Response and Enhances Exercise Capacity[J]. Biorxiv, 2022. https://api.semanticscholar.org/CorpusID:252819965.
[3] Xu W, Billon C, Li H, et al. Abstract 9682: The Cardiac Protective Effects of Novel Synthetic Pan-Estrogen Related Receptor Agonists Slu-pp-332 and Slu-pp-915[J]. Circulation, 2021,144.DOI:10.1161/circ.144.suppl_1.9682.
Product available for research use only:
